{"id":411854,"date":"2025-11-13T13:30:00","date_gmt":"2025-11-13T12:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/dreamm-8-etude-cle-dans-le-developpement-de-la-therapie-bcma-jusqua-dreamm-14\/"},"modified":"2025-11-12T21:50:40","modified_gmt":"2025-11-12T20:50:40","slug":"dreamm-8-etude-cle-dans-le-developpement-de-la-therapie-bcma-jusqua-dreamm-14","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/dreamm-8-etude-cle-dans-le-developpement-de-la-therapie-bcma-jusqua-dreamm-14\/","title":{"rendered":"DREAMM-8 : \u00e9tude cl\u00e9 dans le d\u00e9veloppement de la th\u00e9rapie BCMA jusqu&#8217;\u00e0 DREAMM-14"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Les donn\u00e9es DREAMM-8 pr\u00e9sent\u00e9es \u00e0 l&#8217;ASCO cette ann\u00e9e ont fourni des preuves solides de l&#8217;efficacit\u00e9 et de la tol\u00e9rance de la combinaison BPd (belantamab mafodotin, pomalidomide et dexam\u00e9thasone) dans le traitement du my\u00e9lome multiple r\u00e9cidivant et r\u00e9fractaire (RRMM) avec HRCA (cytog\u00e9n\u00e9tique \u00e0 haut risque). Le BPd, qui offre une alternative viable surtout aux patients atteints d&#8217;HRCA pour lesquels les th\u00e9rapies cellulaires ne sont pas adapt\u00e9es, pourrait s&#8217;\u00e9tablir \u00e0 moyen terme comme traitement de deuxi\u00e8me ligne en Suisse apr\u00e8s sa r\u00e9cente autorisation par Swissmedic &#8211; m\u00eame si le DREAMM-14, pour lequel le dosage lui-m\u00eame devient pour la premi\u00e8re fois un sujet d&#8217;\u00e9tude, pourrait offrir un profil b\u00e9n\u00e9fice\/risque optimis\u00e9 pour les effets secondaires oculaires chez les patients atteints de RRMM. <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fdreamm-8-etude-cle-dans-le-developpement-de-la-therapie-bcma-jusqua-dreamm-14%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Les donn\u00e9es DREAMM-8 pr\u00e9sent\u00e9es \u00e0 l&#8217;ASCO cette ann\u00e9e ont fourni des preuves solides de l&#8217;efficacit\u00e9 et de la tol\u00e9rance de la combinaison BPd (belantamab mafodotin, pomalidomide et dexam\u00e9thasone) dans le&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fdreamm-8-etude-cle-dans-le-developpement-de-la-therapie-bcma-jusqua-dreamm-14%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":411861,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"My\u00e9lome multiple  ","footnotes":"[{\"id\":\"47c4fb67-b024-4175-8a23-577eaa60a3e2\",\"content\":\"C = augmentation du calcium, R = dysfonctionnement r\\u00e9nal, A = an\\u00e9mie, B = l\\u00e9sion osseuse)\"},{\"id\":\"df635557-d508-4f1b-b0fe-d05c3810c624\",\"content\":\"MMAF signifie monom\\u00e9thyllauristatine F, une mol\\u00e9cule cytotoxique qui inhibe la division cellulaire en d\\u00e9stabilisant les microtubules. Elle appartient \\u00e0 la famille des auristatines, initialement d\\u00e9riv\\u00e9e de l'organisme marin Dolabella auricularia. Le linker est le lien biochimique entre l'anticorps et la substance active MMAF. Il fait en sorte que le m\\u00e9dicament reste stable dans le sang, mais qu'il soit lib\\u00e9r\\u00e9 \\u00e0 l'int\\u00e9rieur de la cellule cible (par exemple, la cellule du my\\u00e9lome) d\\u00e8s que le conjugu\\u00e9 a \\u00e9t\\u00e9 absorb\\u00e9. Belamaf utilise un agent de liaison mal\\u00e9imidocaproyle qui est r\\u00e9sistant aux prot\\u00e9ases, c'est-\\u00e0-dire qu'il ne se d\\u00e9grade pas facilement dans le sang.    \"},{\"id\":\"1967fab0-c9f2-44ee-a954-f7d6e9c624d1\",\"content\":\"Blenrep\\u00ae a d'abord \\u00e9t\\u00e9 autoris\\u00e9 en Suisse pour une dur\\u00e9e limit\\u00e9e le 20.06.2022, mais \\u00e0 partir du 28.06.2023, le m\\u00e9dicament n'\\u00e9tait plus autoris\\u00e9.\"},{\"id\":\"ad64f421-8735-43dd-b69c-4ad85b335a9c\",\"content\":\"<a href=\\\"http:\\\/\\\/www.swissmedic.ch\\\/swissmedic\\\/de\\\/home\\\/ueber-uns\\\/publikationen\\\/public-summary-swiss-par-%20blenrep-02\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">www.swissmedic.ch\\\/swissmedic\\\/de\\\/home\\\/ueber-uns\\\/publikationen\\\/public-summary-swiss-par-<br>blenrep-02<\\\/a>\"},{\"id\":\"4bc46feb-c92d-4fac-8104-7e9097e54d40\",\"content\":\"Patients avec un my\\u00e9lome nouvellement diagnostiqu\\u00e9\"},{\"id\":\"02220856-7081-4eb3-9698-99b0a15c1df1\",\"content\":\"Indice de gradation de la qualit\\u00e9 de vie des patients atteints de cancer\"}]","_members_access_role":[],"_members_access_error":""},"category":[11549,11527,11373,11389,11535],"tags":[14761,86171,15036,86164,86158,86169,86161,86167,86173,13859],"powerkit_post_featured":[],"class_list":["post-411854","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-etudes","category-hematologie","category-oncologie","category-rapports-de-congres","tag-asco-fr","tag-belantamab","tag-car-t-fr","tag-combinaison-bpd","tag-dreamm","tag-dreamm-14","tag-dreamm-8","tag-hrca","tag-mafodotin","tag-myelome-multiple","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-28 08:42:53","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":411851,"slug":"dreamm-8-studio-chiave-nello-sviluppo-della-terapia-bcma-fino-a-dreamm-14","post_title":"DREAMM-8: studio chiave nello sviluppo della terapia BCMA fino a DREAMM-14","href":"https:\/\/medizinonline.com\/it\/dreamm-8-studio-chiave-nello-sviluppo-della-terapia-bcma-fino-a-dreamm-14\/"},"pt_PT":{"locale":"pt_PT","id":411856,"slug":"dreamm-8-estudo-chave-no-desenvolvimento-da-terapia-bcma-ate-ao-dreamm-14","post_title":"DREAMM-8: Estudo-chave no desenvolvimento da terapia BCMA at\u00e9 ao DREAMM-14","href":"https:\/\/medizinonline.com\/pt-pt\/dreamm-8-estudo-chave-no-desenvolvimento-da-terapia-bcma-ate-ao-dreamm-14\/"},"es_ES":{"locale":"es_ES","id":411888,"slug":"dreamm-8-estudio-clave-en-el-desarrollo-de-la-terapia-bcma-hasta-el-dreamm-14","post_title":"DREAMM-8: Estudio clave en el desarrollo de la terapia BCMA hasta el DREAMM-14","href":"https:\/\/medizinonline.com\/es\/dreamm-8-estudio-clave-en-el-desarrollo-de-la-terapia-bcma-hasta-el-dreamm-14\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/411854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=411854"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/411854\/revisions"}],"predecessor-version":[{"id":411863,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/411854\/revisions\/411863"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/411861"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=411854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=411854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=411854"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=411854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}